布雷西尤卡布他赛自体细胞疗法治疗复发/难治性B细胞急性淋巴细胞白血病成人患者的疗效和耐受性：一项来自DESCAR-T注册研究的GRAALL研究 - Suppr

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.

作者信息

Rabian Florence, Beauvais David, Marchand Tony, Fürst Sabine, Huynh Anne, Brissot Eolia, Maury Sébastien, Gabellier Ludovic, Chevallier Patrice, Loschi Michael, Nguyen Stéphanie, Balsat Marie, Lafon Ingrid, Fayard Amandine, Camus Vincent, Simand Célestine, Moya Niels, Castilla-Llorente Cristina, Joris Magalie, Berceanu Ana, Thiebaut-Bertrand Anne, Lhéritier Véronique, Gehlkopf Eve, Roth-Guépin Gabrielle, Leguay Thibaut, Boissel Nicolas

机构信息

Hematology Adolescents and Young Adult Division, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.

Unité de Recherche Propre (URP-)3518, Institut de Recherche Saint-Louis, Université de Paris Cité, Paris, France.

出版信息

Blood Adv. 2024 Nov 12;8(21):5493-5496. doi: 10.1182/bloodadvances.2024013962.

DOI:10.1182/bloodadvances.2024013962

PMID:39207868

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11532742/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f93d/11532742/05087b945445/BLOODA_ADV-2024-013962-gr1.jpg

相似文献

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.布雷西尤卡布他赛自体细胞疗法治疗复发/难治性B细胞急性淋巴细胞白血病成人患者的疗效和耐受性：一项来自DESCAR-T注册研究的GRAALL研究

Blood Adv. 2024 Nov 12;8(21):5493-5496. doi: 10.1182/bloodadvances.2024013962.

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.布雷西尤卡布他赛在复发或难治性套细胞淋巴瘤中的应用，DESCAR-T注册研究中的意向性治疗

Haematologica. 2024 Nov 1;109(11):3745-3750. doi: 10.3324/haematol.2023.284786.

Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.布雷西尤单抗自体白细胞介素用于复发/难治性套细胞淋巴瘤的成本效益

Leuk Lymphoma. 2023 Jul-Aug;64(8):1442-1450. doi: 10.1080/10428194.2023.2215888. Epub 2023 May 25.

[DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].[DESCAR-T，法国全国性的接受CAR-T细胞治疗患者登记系统]

Bull Cancer. 2021 Oct;108(10S):S143-S154. doi: 10.1016/j.bulcan.2021.07.002.

Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma.布雷西尤卡布他赛：一种用于治疗套细胞淋巴瘤的新型嵌合抗原受体T细胞疗法。

Ann Pharmacother. 2022 May;56(5):609-619. doi: 10.1177/10600280211026338. Epub 2021 Aug 2.

Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.阿基仑赛注射液和倍利妥注射液治疗复发/难治性弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤。

Future Oncol. 2021 Apr;17(11):1269-1283. doi: 10.2217/fon-2020-0291. Epub 2021 Jan 15.

Case Rep Oncol. 2024 Sep 26;17(1):1087-1093. doi: 10.1159/000541256. eCollection 2024 Jan-Dec.

Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.批准 brexucabtagene autoleucel 用于治疗成人复发/难治性急性淋巴细胞白血病。

Blood. 2022 Jul 7;140(1):11-15. doi: 10.1182/blood.2021014892.

FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.FDA 批准概要：Brexucabtagene Autoleucel 治疗复发或难治性 B 细胞前体急性淋巴细胞白血病成人患者。

Oncologist. 2022 Oct 1;27(10):892-899. doi: 10.1093/oncolo/oyac163.

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.ZUMA-2 方案与 SCHOLAR-2 标准治疗方案治疗复发/难治性套细胞淋巴瘤的间接治疗比较

Leuk Lymphoma. 2024 Jan;65(1):14-25. doi: 10.1080/10428194.2023.2268228. Epub 2024 Jan 10.

引用本文的文献

[CAR T cell therapy in acute lymphoblastic leukemia].[嵌合抗原受体T细胞疗法治疗急性淋巴细胞白血病]

Inn Med (Heidelb). 2025 Jul 15. doi: 10.1007/s00108-025-01949-7.

Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.复发/难治性中枢神经系统受累急性淋巴细胞白血病患者使用brexucabtagene autoleucel的疗效

Blood Adv. 2025 Aug 26;9(16):4081-4089. doi: 10.1182/bloodadvances.2024015779.

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.将布雷西尤卡布他赛作为复发/难治性B细胞急性淋巴细胞白血病成人患者的标准疗法后的疗效

J Clin Oncol. 2025 Feb 10;43(5):558-566. doi: 10.1200/JCO.24.00321. Epub 2024 Oct 17.

本文引用的文献

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.ZUMA-3 研究中，既往治疗和随后的移植对复发/难治性 B 细胞急性淋巴细胞白血病成人患者接受 brexucabtagene autoleucel 治疗结局的影响。

J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007118.

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.CD19 CAR T 细胞是治疗 B 细胞系 ALL 移植后复发的有效方法：来自德国的真实世界数据。

Blood Adv. 2023 Jun 13;7(11):2436-2448. doi: 10.1182/bloodadvances.2022008981.

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.ELIANA 试验中复发/难治性急性淋巴细胞白血病的儿科和年轻成年患者接受 tisagenlecleucel 治疗的 3 年更新结果。

J Clin Oncol. 2023 Mar 20;41(9):1664-1669. doi: 10.1200/JCO.22.00642. Epub 2022 Nov 18.

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.Blinatumomab 无应答和高疾病负担与 CD19-CAR 治疗 B-ALL 后的不良结局相关。

J Clin Oncol. 2022 Mar 20;40(9):932-944. doi: 10.1200/JCO.21.01405. Epub 2021 Nov 12.

CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.针对中枢神经系统复发或难治性急性淋巴细胞白血病的 CD19 靶向嵌合抗原受体 T 细胞疗法：五项临床试验 pooled data 的事后分析。

Lancet Haematol. 2021 Oct;8(10):e711-e722. doi: 10.1016/S2352-3026(21)00238-6.

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.泽沃基奥仑赛注射液（KTE-X19）治疗复发或难治性成人 B 细胞急性淋巴细胞白血病：ZUMA-3 研究单臂、开放标签、多中心的 2 期结果。

Lancet. 2021 Aug 7;398(10299):491-502. doi: 10.1016/S0140-6736(21)01222-8. Epub 2021 Jun 4.

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.tisagenlecleucel 治疗 B 细胞急性淋巴细胞白血病后 CD19 阳性与 CD19 阴性复发的决定因素。

Leukemia. 2021 Dec;35(12):3383-3393. doi: 10.1038/s41375-021-01281-7. Epub 2021 May 17.

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.替沙格赛定用于儿童急性淋巴细胞白血病和非霍奇金淋巴瘤的真实世界证据。

Blood Adv. 2020 Nov 10;4(21):5414-5424. doi: 10.1182/bloodadvances.2020003092.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献